Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with ...

凭借250亿美元的销售额，默沙东K药成功取代修美乐，登顶2023年“药王”宝座。

The treatment, known by brand name Mylotarg (gemtuzumab ozogamicin), was given marketing authorisation by the FDA in 2000 for the treatment of acute myeloid leukaemia (AML). Clinical trial data ...

Vor Biopharma Inc.的股价已跌至52周新低，触及0.69美元，这家生物技术公司正面临着充满挑战的市场环境。这一最新价格标志着公司股价的显著下跌，过去一年里其股价已下跌66.04%。投资者正密切关注Vor Biopharma的表现，因为该公司正在生物技术板块的波动中寻找方向，希望能出现潜在反弹或可能影响其市场地位的战略性发展。

Orum said recently that preclinical results with ORM-6151 suggest it should offer better tolerability than Pfizer’s Mylotarg (gemtuzumab ozogamicin), a CD33-targeting ADC that has been approved ...

After hours: September 25 at 5:58 PM EDT Loading Chart for VOR ...